Your Template Here
Create an HTML page using whatever layout and sizing you like. Link to your own stylesheets for consistency with your main website. Then place the word [ minisite ] where you want our MiniSite to appear. Our system automatically inserts the latest content and serves it to your readers.
Navigation
When your navigation changes, you can log into our admin panel and upload a new template. Or, just use an iframe to share code from your main website. We don't stand between you and your regular web updates.
In addition to your standard site navigation, MiniSites are a great place to link to existing revenue drivers. You can create any connections you like between different areas of your site. MiniSites can offer gateways to:
- Coupons
- Directories
- Mini-sites
- Storefronts
- And more!
 |
||||
Breast Cancer Treatments Go Meta 
Metastasis via the blood stream is the most common cause of death in breast cancer patients, but a new medical finding could soon make it testable and, ultimately, more easily preventable. In a new study by New York-Presbyterian Hospital/Weill Cornell Medical Center, funded by the National Cancer Institute, researchers identified a new breast cancer metastasis marker called Tumor Microenvironment of Metastasis (TMEM). The density of the TMEM-marker was more than double in patients that developed systemic metastases compared with the patients with only localized breast cancer. “Currently, anyone with a breast cancer diagnosis fears the worst, that the cancer will spread and threaten their lives,” says senior author Dr. Joan G. Jones, professor of clinical pathology and laboratory medicine at Weill Cornell Medical College. “A tissue test for metastatic risk could alleviate those worries, and prevent toxic and costly measures like radiation and chemotherapy.” According to the National Cancer Institute, 40 percent of breast cancer patients suffer a relapse and develop metastatic disease, and more than 40,000 women die from it each year. “If patients can be better classified as either low risk or high risk for metastasis, therapies can be custom tailored to patients, preventing over-treatment or under-treatment of the disease,” says Dr. Brian D. Robinson, resident in Anatomic Pathology at NewYork-Presbyterian Hospital/Weill Cornell Medical Center and co-author of the study. The discovery could directly impact survival rates by giving doctors the ability to assess each individual’s likelihood to develop metastasis based on more accurate information. "Traditionally, the likelihood of breast cancer metastasis is estimated based on tumor size, tumor differentiation – how similar or dissimilar the tumor is compared to normal breast tissue – and whether it has spread to the lymph nodes,” Jones says. “While these are useful measures, TMEM density directly reflects the blood-borne mechanism of metastasis, and therefore may prove to be more specific and directly relevant.”
|
||||
|
||||
Advertisements
You can use the space around the MiniSite content to create multiple ad and sponsorship positions that you can customize to your market. In fact, you can create a premium sponsorship opportunity by inserting ads or custom navigation inside the MiniSite area using a special feature in our system.
If you use JavaScript tags for ad serving or site tracking, you can add them to your template, and manage your MiniSite pages with the same tools you use to manage the rest of your site.
Footer